Latest news
FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer - The American Journal of Managed CareThe American Journal of Managed Care · Fri, 07 Aug 2026 19:00:00 GMTKelun-Biotech's TROP2 ADC sac-TMT Advances Toward First-Line TNBC Approval in China - BioPharma APACBioPharma APAC · Sun, 02 Aug 2026 18:34:30 GMTDaiichi Sankyo wins EU approval for Datroway in TNBC - International Business TimesInternational Business Times · Fri, 31 Jul 2026 16:15:40 GMTEU approves Datroway as first TROP2 ADC with overall survival benefit in first-line metastatic TNBC - AllSciAllSci · Fri, 31 Jul 2026 12:33:31 GMTDatroway approved in the EU for metastatic TNBC - The Pharma LetterThe Pharma Letter · Fri, 31 Jul 2026 11:19:47 GMTDatroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy - finance.yahoo.comfinance.yahoo.com · Fri, 31 Jul 2026 06:30:00 GMTDatroway approved in the EU as only TROP2-directed medicine with overall survival benefit for the 1st-line treatment of patients with metastatic TNBC who are not candidates for immunotherapy - AstraZenecaAstraZeneca · Fri, 31 Jul 2026 02:00:00 GMTFDA Approves Two New Treatments For Metastatic TNBC - Breast Cancer.orgBreast Cancer.org · Wed, 29 Jul 2026 07:00:00 GMT